Zobrazeno 1 - 10
of 81
pro vyhledávání: ''
Autor:
A Arencibia-Domínguez, Catalina Falo, Miguel Gil-Gil, N Manent-Molina, S Salinas-Huertas, G Campos, S Vázquez-Gallego, Hector Perez-Montero, Amparo Garcia-Tejedor, M Ortí-Asencio, M Campos-Delgado, F Tormo-Collado, A Guma, A Mestre-Jane, M Beranuy-Rodriguez, M.L. Catasús-Clavé, A Benítez-Segura, Sonia Pernas, A Luzardo-González, J Terra, M Gomila-Sancho, E Martinez-Perez, R Planas-Balagué, María Jesús Pla, J Ponce-Sebastià, B Gonzalez-Pineda, Y Valverde-Alcántara, Ana Belén Trelles Rodríguez, María E. Fernández-Montolí, M Jaraba-Armas, I Campos-Varela
Publikováno v:
Breast Disease. 41:97-108
INTRODUCTION: The Objective was to investigate the incidence of lymphedema after breast cancer treatment and to analyze the risk factors involved in a tertiary level hospital. METHODS: Prospective longitudinal observational study over 3 years post-br
Autor:
Linu Abraham Jacob, M C Suresh Babu, Smitha Saldanha, L K Rajeev, A H Rudresha, K N Lokesh, Usha Amirtham, A. Thottian, D. Lokanatha, Shina Goyal
Publikováno v:
Breast Disease. 41:115-121
BACKGROUND: The present era of individualized treatment for breast cancer is influenced by the initial disease status including the anatomical extent, grade, and receptor status. An accurate preoperative staging is the basis of treatment planning and
Autor:
Yukiko Miyamura, Shunji Kamigaki, Jun Yamamura, Yukihiko Hahimot, Hironobu Manabe, Yoshifumi Komoike, Toshikazu Ito, Junya Fujita, Yumiko Tanaka, Hiroki Osato, Wataru Shinzaki
Publikováno v:
Breast Disease. 41:109-114
BACKGROUND: Current guidelines define primary and secondary endocrine resistance according to the periods of adjuvant endocrine therapy (adj-ET); however, the relationship between adj-ET period and endocrine resistance remains unclear. OBJECTIVE: We
Autor:
Giovanni Pierorazio, Francesco Pavese, Giampiero Porzio, Katia Cannita, V. Cocciolone, Lucilla Verna, Silvia Rotondaro, Corrado Ficorella, Tina Sidoni, Alessandro Parisi
Publikováno v:
Breast Disease. 40:257-262
BACKGROUND: Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20–45% of them will experience a disease recurrence, particularly bone metastases in 60–80% of cases, which occur more frequently in luminal
Autor:
Atanas Ignatov, Piotr Czapiewski, Thomas Kalinski, Willi Pieper, Norbert Nass, Johannes Haybaeck
Publikováno v:
Cancer Biomarkers. 32:161-173
BACKGROUND: Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers. OBJECTIVE: Here, we investigated whether NNAT is also a predictive biomarker
Publikováno v:
Breast Disease. 40:213-218
Mammogram is the standard imaging modality for the early detection of breast cancer, and it has been shown to reduce disease-related mortality by up to 30%. Mammogram, however, has its limitations. It is reported that 10–30% of breast cancers may b
Publikováno v:
Breast Disease. 40:177-182
BACKGROUND: Of the most common imaging modalities for breast cancer diagnosis – mammogram (MAM), ultrasound (US), magnetic resonance imaging (MRI) – it has not been well established which of these most accurately corresponds to the histological t
Publikováno v:
Breast Disease. 40:S33-S37
BACKGROUND: Increased plasma aldehyde dehydrogenase 1 (ALDH1) levels have been proposed to predict cancer chemoresistance. However, studies have reported inconsistent results, depending on the type of cancer cells used. OBJECTIVE: This study aimed to
Autor:
Gita Vita Soraya, Prihantono Prihantono, Muhammad Faruk, Salman Ardy Syamsu, John Pieter Junior, Septiman Septiman, Okto Sampe Padang, Elridho Sampepajung
Publikováno v:
Breast Disease. 40:S77-S84
BACKGROUND: Breast cancer, a global health problem with a high mortality rate, has several risk factors, including obesity and increased lipid profile. Postmenopausal obesity is associated with estrogen production from adipose tissue, while abnormal
Publikováno v:
Breast Disease. 40:S1-S7
BACKGROUND: The plasminogen urokinase activation system consists of urokinase plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor type 1 (PAI-1), which are considered to have a relationship with cancer aggressiveness.